Shares of NovoCure Ltd. (NVCR), a pioneer in tumor-treating fields therapy, surged 5.94% on October 30 after the company reported robust third-quarter financial results that exceeded analysts' expectations. The stock rally reflected investors' optimism surrounding NovoCure's continued growth trajectory and regulatory advancements.

NovoCure's revenue for the quarter ended September 30 climbed 21.8% year-over-year to $155.1 million, outpacing the consensus estimate of $143.95 million. The company's flagship products, Optune Gio and Optune Lua, continued to drive sales, with the U.S. market contributing $98.3 million and France and Japan generating $15.2 million and $8.6 million, respectively.

While NovoCure reported a net loss of $30.6 million, its non-GAAP loss per share of $0.28 was narrower than the expected loss of $0.33. Additionally, the company's adjusted EBITDA turned positive at $1.7 million, a significant improvement from a loss of $29.1 million in the same quarter last year, reflecting its efforts to manage costs effectively.